Systems approach for congruence and selection of cancer models towards precision medicine

Jian Zou,Osama Shah,Yu-Chiao Chiu,Tianzhou Ma,Jennifer M. Atkinson,Steffi Oesterreich,Adrian V. Lee,George C. Tseng

DOI: https://doi.org/10.1371/journal.pcbi.1011754

2024-01-11

PLoS Computational Biology

Abstract:Cancer models are instrumental as a substitute for human studies and to expedite basic, translational, and clinical cancer research. For a given cancer type, a wide selection of models, such as cell lines, patient-derived xenografts, organoids and genetically modified murine models, are often available to researchers. However, how to quantify their congruence to human tumors and to select the most appropriate cancer model is a largely unsolved issue. Here, we present Congruence Analysis and Selection of CAncer Models (CASCAM), a statistical and machine learning framework for authenticating and selecting the most representative cancer models in a pathway-specific manner using transcriptomic data. CASCAM provides harmonization between human tumor and cancer model omics data, systematic congruence quantification, and pathway-based topological visualization to determine the most appropriate cancer model selection. The systems approach is presented using invasive lobular breast carcinoma (ILC) subtype and suggesting CAMA1 followed by UACC3133 as the most representative cell lines for ILC research. Two additional case studies for triple negative breast cancer (TNBC) and patient-derived xenograft/organoid (PDX/PDO) are further investigated. CASCAM is generalizable to any cancer subtype and will authenticate cancer models for faithful non-human preclinical research towards precision medicine. Cancer research relies on models, such as cell lines, patient-derived xenografts (PDX), and patient-derived organoids (PDO), as essential alternatives to human studies. However, it is crucial to determine how well these models mimic human patients and to quantify their congruence in disease-relevant genes and regulatory pathways. As the number of cancer models grows, researchers face the challenge of selecting the most representative model based on molecular profiles. Existing methods are machine learning based and are limited to prediction using genome-wide information without mechanistic insights. To address this, we developed a comprehensive suite of bioinformatics tools, namely Congruence Analysis and Selection of CAncer Models (CASCAM). The framework develops a multi-stage systems approach to quantify pathway and gene specific congruence and allow prioritization and selection of the most congruent cancer model(s), which provides a paradigm shift towards gene regulatory and systems investigations.

biochemical research methods,mathematical & computational biology